- Alliance Partners
- Homepage
- Clinical Trials
- Disease Areas
- Molecules
- Avadomide (CC-122; Cereblon Targeting Agent)
- Azacitidine (DNA Methyltransferase Inhibitor)
- bb2121 (Anti-BCMA CAR T)
- CC-486 (DNA Methyltransferase Inhibitor)
- CC-90002 (Anti-CD47 Antibody)
- Enasidenib (IDH2 Inhibitor)
- Lenalidomide (IMiD® Agent)
- Luspatercept
- Lisocabtagene Maraleucel (Liso-Cel; JCAR017; Anti-CD19 CAR T Cells)
- Marizomib (Proteasome Inhibitor)
- nab-Paclitaxel (Albumin-Bound Microtubule Inhibitor)
- Pomalidomide (IMiD® Agent)
- Romidepsin (Histone Deacetylase Inhibitor)
- Tislelizumab (BGB-A317; Anti–PD-1 Monoclonal Antibody)
- Pathways
- Immuno-Oncology
- Activity of IMiD® Agents
- Combining Hypomethylating and Immuno-Oncology Agents
- Combining Chemotherapy and Immuno-Oncology Agents
- Checkpoint Inhibition (PD-1/PD-L1)
- Macrophage Activation (CD47)
- B-Cell Maturation Antigen (BCMA)
- B-Cell Differentiation (CD19)
- Chimeric Antigen Receptor (CAR) T Cells
- Inducible T-Cell Costimulator (ICOS)
- Epigenetics
- Protein Homeostasis
- Biotherapeutics and Novel Targets
- Immuno-Oncology
- Pipeline
- Research Partners
- Resources